top of page
logo.webp

Copenhagen

ISPOR Europe 2023

p2.png

Patients Level Cost of Treating Adverse Events in Alzheimer's Disease for US-FDA Approved Treatments

Authors:

vaski.jpeg

Vassiki Sanogo

reem.jpg

Reem Dhayan Almutair

images.png

Vakaramoko Diaby

Gallery:

PHOTO-2024-12-19-17-47-44.jpg
PHOTO-2024-12-19-17-47-53.jpg
PHOTO-2024-12-19-17-49-15.jpg

Research Heading

Poster session presented at
ISPOR Europe 2023 (12-15November)

Budget Impact of Memantine for Alzheimer's Patient in the United State

Authors:

reem.jpg

Reem Dhayan Almutair

vaski.jpeg

Vassiki Sanogo

images.png

Vakaramoko Diaby

Gallery:

PHOTO-2024-12-19-17-47-00(7).jpg
PHOTO-2024-12-19-17-47-00(3).jpg
PHOTO-2024-12-19-17-47-00(4).jpg

Research Heading

Poster session presented at
ISPOR Europe 2023 (12-15November)

Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)

Authors:

reem.jpg

Reem Dhayan Almutair

vaski.jpeg

Vassiki Sanogo

images.png

Vakaramoko Diaby

Gallery:

PHOTO-2024-12-19-17-47-00(5).jpg
PHOTO-2024-12-19-17-47-00(6).jpg
PHOTO-2024-12-19-17-47-00.jpg

Research Heading

Poster session presented at
ISPOR Europe 2023 (12-15November)

Safety Profile of Approved Alzheimer's Medication by USFDA

Authors:

reem.jpg

Reem Dhayan Almutair

vaski.jpeg

Vassiki Sanogo

images.png

Vakaramoko Diaby

Gallery:

PHOTO-2024-12-19-17-49-57.jpg
PHOTO-2024-12-19-17-47-00(2).jpg
PHOTO-2024-12-19-17-47-00(1).jpg

Research Heading

Poster session presented at
ISPOR Europe 2023 (12-15November)

Empowered Business Leaders

#careersatintegrity

#jointheteam

Connect Us
logo.png
  • LinkedIn
  • X

Our insights direct to your inbox

bottom of page